Galectin Historical Income Statement

GALT Stock

USD 2.69 0.03 1.10%

Historical analysis of Galectin Therapeutics income statement accounts such as Other Operating Expenses of 40 M or Research Development of 33.7 M can show how well Galectin Therapeutics performed in making a profits. Evaluating Galectin Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Galectin Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Galectin Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Galectin Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galectin Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide.

About Galectin Income Statement Analysis

Galectin Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Galectin Therapeutics shareholders. The income statement also shows Galectin investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Galectin Therapeutics Income Statement Chart

At this time, Galectin Therapeutics' Depreciation And Amortization is comparatively stable compared to the past year. Other Operating Expenses is likely to gain to about 40 M in 2024, despite the fact that Operating Income is likely to grow to (36.2 M).

Selling General Administrative Other Operating Expenses Research Development Total Operating Expenses

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Galectin Therapeutics. It is also known as Galectin Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Galectin Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Galectin Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galectin Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide.At this time, Galectin Therapeutics' Depreciation And Amortization is comparatively stable compared to the past year. Other Operating Expenses is likely to gain to about 40 M in 2024, despite the fact that Operating Income is likely to grow to (36.2 M).

Galectin Therapeutics income statement Correlations

	Depreciation And Amortization	Selling General Administrative	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Gross Profit	Cost Of Revenue	Net Income From Continuing Ops	Non Operating Income Net Other	Interest Income	Net Interest Income	Reconciled Depreciation	Selling And Marketing Expenses
Depreciation And Amortization		0.17	0.06	-0.06	-0.06	0.04	-0.06	0.06	-0.06	0.04	-0.06	-0.23	0.22	-0.22	0.01	0.51	0.7	0.01	0.5	0.01
Selling General Administrative	0.17		0.36	-0.38	-0.38	0.23	-0.38	0.37	-0.37	-0.05	-0.37	-0.81	0.9	-0.9	-0.15	-0.1	-0.01	-0.06	0.1	-0.01
Other Operating Expenses	0.06	0.36		-1.0	-1.0	0.99	-1.0	1.0	-1.0	-0.69	-1.0	-0.16	0.46	-0.46	-0.97	0.21	0.34	-0.82	0.7	0.61
Operating Income	-0.06	-0.38	-1.0		1.0	-0.99	1.0	-1.0	1.0	0.66	1.0	0.18	-0.47	0.47	0.96	-0.2	-0.31	0.8	-0.71	-0.59
Ebit	-0.06	-0.38	-1.0	1.0		-0.99	1.0	-1.0	1.0	0.66	1.0	0.18	-0.47	0.47	0.96	-0.2	-0.31	0.8	-0.71	-0.59
Research Development	0.04	0.23	0.99	-0.99	-0.99		-0.99	0.99	-0.99	-0.71	-0.99	-0.04	0.35	-0.35	-0.99	0.23	0.35	-0.85	0.72	0.64
Ebitda	-0.06	-0.38	-1.0	1.0	1.0	-0.99		-1.0	1.0	0.66	1.0	0.17	-0.47	0.47	0.96	-0.2	-0.3	0.8	-0.71	-0.59
Total Operating Expenses	0.06	0.37	1.0	-1.0	-1.0	0.99	-1.0		-1.0	-0.69	-1.0	-0.16	0.46	-0.46	-0.97	0.21	0.33	-0.82	0.7	0.61
Income Before Tax	-0.06	-0.37	-1.0	1.0	1.0	-0.99	1.0	-1.0		0.7	1.0	0.15	-0.46	0.46	0.97	-0.2	-0.34	0.84	-0.71	-0.64
Total Other Income Expense Net	0.04	-0.05	-0.69	0.66	0.66	-0.71	0.66	-0.69	0.7		0.7	-0.19	-0.13	0.13	0.75	-0.07	-0.6	0.94	-0.43	-0.94
Net Income	-0.06	-0.37	-1.0	1.0	1.0	-0.99	1.0	-1.0	1.0	0.7		0.15	-0.46	0.46	0.97	-0.2	-0.33	0.83	-0.71	-0.63
Income Tax Expense	-0.23	-0.81	-0.16	0.18	0.18	-0.04	0.17	-0.16	0.15	-0.19	0.15		-0.89	0.89	-0.09	0.11	0.05	-0.19	0.06	0.16
Gross Profit	0.22	0.9	0.46	-0.47	-0.47	0.35	-0.47	0.46	-0.46	-0.13	-0.46	-0.89		-1.0	-0.23	0.03	0.1	-0.15	0.2	0.1
Cost Of Revenue	-0.22	-0.9	-0.46	0.47	0.47	-0.35	0.47	-0.46	0.46	0.13	0.46	0.89	-1.0		0.23	-0.03	-0.1	0.15	-0.21	-0.1
Net Income From Continuing Ops	0.01	-0.15	-0.97	0.96	0.96	-0.99	0.96	-0.97	0.97	0.75	0.97	-0.09	-0.23	0.23		-0.21	-0.35	0.89	-0.71	-0.69
Non Operating Income Net Other	0.51	-0.1	0.21	-0.2	-0.2	0.23	-0.2	0.21	-0.2	-0.07	-0.2	0.11	0.03	-0.03	-0.21		0.42	-0.19	0.47	0.15
Interest Income	0.7	-0.01	0.34	-0.31	-0.31	0.35	-0.3	0.33	-0.34	-0.6	-0.33	0.05	0.1	-0.1	-0.35	0.42		-0.53	0.5	0.64
Net Interest Income	0.01	-0.06	-0.82	0.8	0.8	-0.85	0.8	-0.82	0.84	0.94	0.83	-0.19	-0.15	0.15	0.89	-0.19	-0.53		-0.56	-0.88
Reconciled Depreciation	0.5	0.1	0.7	-0.71	-0.71	0.72	-0.71	0.7	-0.71	-0.43	-0.71	0.06	0.2	-0.21	-0.71	0.47	0.5	-0.56		0.43
Selling And Marketing Expenses	0.01	-0.01	0.61	-0.59	-0.59	0.64	-0.59	0.61	-0.64	-0.94	-0.63	0.16	0.1	-0.1	-0.69	0.15	0.64	-0.88	0.43

Click cells to compare fundamentals

Galectin Therapeutics Account Relationship Matchups

Galectin Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	266K	66K	3K	52K	33K	44.8K
Selling General Administrative	6.0M	5.5M	6.4M	6.6M	5.9M	5.3M
Other Operating Expenses	13.4M	23.4M	30.2M	38.4M	38.1M	40.0M
Operating Income	(13.4M)	(23.4M)	(30.2M)	(38.4M)	(38.1M)	(36.2M)
Ebit	(13.4M)	(23.4M)	(30.2M)	(38.4M)	(38.1M)	(36.2M)
Research Development	7.5M	18.0M	23.8M	31.7M	32.1M	33.7M
Ebitda	(13.2M)	(23.4M)	(30.2M)	(38.3M)	(38.0M)	(36.1M)
Total Operating Expenses	13.4M	23.4M	30.2M	38.4M	38.0M	39.9M
Income Before Tax	(13.3M)	(23.5M)	(30.5M)	(38.8M)	(41.1M)	(39.0M)
Total Other Income Expense Net	144K	(21K)	(348K)	(424K)	(3.0M)	(2.8M)
Net Income	(13.4M)	(23.5M)	(31.0M)	(39.2M)	(41.1M)	(39.0M)
Income Tax Expense	87K	51K	448K	424K	487.6K	512.0K
Gross Profit	(35K)	(36K)	(41K)	(32K)	(33K)	(34.7K)
Cost Of Revenue	35K	36K	41K	32K	33K	31.4K
Preferred Stock And Other Adjustments	1.2M	1.1M	263K	137K	123.3K	117.1K
Net Income From Continuing Ops	(13.3M)	(23.5M)	(30.5M)	(38.8M)	(41.7M)	(39.6M)
Non Operating Income Net Other	24K	38K	231K	66K	75.9K	79.7K
Net Income Applicable To Common Shares	(20.2M)	(23.6M)	(30.7M)	(38.9M)	(35.0M)	(36.7M)
Interest Income	38K	231K	66K	3K	186K	195.3K
Net Interest Income	144K	(21K)	(486K)	(981K)	(2.1M)	(2.0M)
Reconciled Depreciation	35K	36K	41K	32K	36.8K	27.8K

Pair Trading with Galectin Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Galectin Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Galectin Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Galectin Stock

0.82	EYEN	Eyenovia	Pair Corr
0.79	JNJ	Johnson Johnson Financial Report 18th of July 2024	Pair Corr
0.74	ETON	Eton Pharmaceuticals	Pair Corr
0.73	LRMR	Larimar Therapeutics Trending	Pair Corr
0.71	KOD	Kodiak Sciences Earnings Call Today	Pair Corr

The ability to find closely correlated positions to Galectin Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Galectin Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Galectin Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Galectin Therapeutics to buy it.

The correlation of Galectin Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Galectin Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Galectin Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Galectin Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Galectin Stock Analysis

When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Galectin Historical Income Statement

About Galectin Income Statement Analysis

Galectin Therapeutics Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Galectin Therapeutics income statement Correlations

Galectin Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Galectin Therapeutics income statement Accounts

Pair Trading with Galectin Therapeutics

Moving against Galectin Stock

Additional Tools for Galectin Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Depreciation And Amortization	Interest Expense
Selling General Administrative	Other Operating Expenses
Operating Income	Ebit
Research Development	Ebitda
Total Operating Expenses	Income Before Tax
Total Other Income Expense Net	Net Income
Income Tax Expense	Gross Profit
Cost Of Revenue	Total Revenue
Preferred Stock And Other Adjustments	Net Income From Continuing Ops
Non Operating Income Net Other	Net Income Applicable To Common Shares
Interest Income	Net Interest Income
Reconciled Depreciation	Selling And Marketing Expenses

Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit

Cost Of Revenue	- 1.0	Gross Profit
Net Income	- 1.0	Total Operating Expenses
Income Before Tax	- 1.0	Total Operating Expenses
Total Operating Expenses	- 1.0	Ebitda
Total Operating Expenses	- 1.0	Ebit
Total Operating Expenses	- 1.0	Operating Income